Breast Imaging — MCQs

Q: For normal mammography, what is the nominal focal size of the X-ray tube used?

0.3-0.35 mm. In mammography, high spatial resolution is critical for detecting tiny structures like microcalcifications. The focal spot size directly influences **geometric blurring** (penumbra); a smaller focal spot results in a sharper image. ### 1. Why Option B is Correct For **routine (normal) mammography**, a nominal focal spot size of **0.3 mm** (typically ranging from 0.3 to 0.35 mm) is the standard. This size provides an optimal balance: it is small enough to ensure high detail for screening while being large enough to withstand the heat generated by the X-ray tube during standard exposures without damaging the anode. ### 2. Why Other Options are Incorrect * **Option A (0.2-0.25 mm):** This is too large for magnification but smaller than the standard for routine screening. * **Options C & D (0.4-0.5 mm):** These sizes are used in general radiography (e.g., Chest X-rays, where focal spots are often 0.6–1.2 mm). In mammography, such large spots would cause excessive geometric blurring, making it impossible to see fine architectural distortions. ### 3. High-Yield Clinical Pearls for NEET-PG * **Magnification Mammography:** When a specific area needs to be magnified, a much smaller focal spot of **0.1 mm** (range 0.1–0.15 mm) is used to compensate for the increased blurring caused by the air gap. * **Anode Material:** Usually **Molybdenum (Mo)** or Rhodium (Rh) is used to produce low-energy (soft) X-rays (25–30 kVp) for better soft-tissue contrast. * **Orientation:** The cathode is placed over the **base of the breast** (chest wall) and the anode over the **apex** (nipple) to utilize the "Heel Effect" for uniform density.

Q: What is the typical radiation dose delivered during mammography?

0.1 centiGray/study. ### Explanation **1. Why Option C is Correct:** The radiation dose in mammography is measured as the **Mean Glandular Dose (MGD)**, which represents the average dose to the radiosensitive glandular tissue of the breast. For a standard two-view screening mammogram (per breast), the typical dose is approximately **1 to 2 mGy (0.1 to 0.2 rad)**. Since **1 rad = 1 centiGray (cGy)**, a dose of 0.1 rad is equivalent to **0.1 cGy**. This level of radiation is considered very low and is roughly equivalent to the amount of natural background radiation a person receives over seven weeks. **2. Why Other Options are Incorrect:** * **Option A (0.1 Gray):** This is equivalent to 100 mGy. This dose is far too high for diagnostic imaging and would be closer to levels used in therapeutic radiation or causing deterministic effects. * **Option B (0.01 cGy):** This is 0.1 mGy, which is too low to produce a diagnostic quality image of dense breast tissue. * **Option D (0.01 Gray):** This is equivalent to 10 mGy (1 rad). While some complex interventional procedures might reach this level, it is significantly higher than the standard dose for a screening mammogram. **3. High-Yield Clinical Pearls for NEET-PG:** * **Target/Filter Material:** Mammography uses low-energy X-rays (typically **25–35 kVp**) to maximize soft tissue contrast. Common target/filter combinations are **Molybdenum/Molybdenum** or **Rhodium**. * **MQSA Requirement:** The Mammography Quality Standards Act (MQSA) mandates that the dose should not exceed **3 mGy (0.3 cGy)** per view with a grid. * **Screening Guidelines:** In India, the general recommendation is annual or biennial screening starting at age 40–50 years. * **Risk vs. Benefit:** The risk of radiation-induced breast cancer is negligible compared to the benefit of early detection of spontaneous breast cancer.

Q: Which of the following is NOT an indication of malignancy on mammography?

Nodular calcification. ### Explanation In mammography, the primary goal is to differentiate between benign and malignant features based on mass morphology, margins, and calcification patterns. **1. Why "Nodular Calcification" is the correct answer:** Nodular (or "popcorn-like") calcifications are typically large, coarse, and well-defined. These are classic features of **benign** lesions, most commonly seen in **involuting fibroadenomas**. Malignant calcifications, by contrast, are usually pleomorphic, fine-linear, or branching (casting type), representing necrotic debris within ducts (as seen in DCIS). **2. Analysis of Incorrect Options (Malignant Features):** * **Speckled (Spiculated) Margin:** This is the most specific mammographic sign of malignancy. It represents the infiltration of cancer cells into surrounding tissue and the subsequent desmoplastic reaction. * **Attenuated (Distorted) Architecture:** Architectural distortion refers to the pulling or tethering of normal breast parenchyma without a visible central mass. While it can occur in post-surgical scars, in a screening context, it is highly suspicious for invasive lobular or ductal carcinoma. * **Irregular Mass:** Malignant tumors grow haphazardly, leading to an irregular shape. Benign lesions are more likely to be round, oval, or circumscribed. **3. High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS Classification:** Used for standardized reporting. BI-RADS 4 and 5 indicate high suspicion of malignancy. * **Most specific sign of malignancy:** Spiculated margins. * **Benign Calcifications:** Popcorn (Fibroadenoma), Eggshell/Rim (Oil cysts), and Teardrop (Milk of calcium). * **Malignant Calcifications:** Fine pleomorphic or fine-linear branching (BI-RADS 5). * **Initial Investigation:** Mammography is the gold standard for screening women >40 years; Ultrasound is preferred for women <30 years or during pregnancy/lactation.

Q: What is the primary purpose of the BIRADS score?

To maintain uniformity in the reporting of imaging findings of various breast diseases. **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized quality assurance tool developed by the American College of Radiology (ACR). Its primary objective is to **standardize breast imaging reporting**, reduce ambiguity in interpretations, and facilitate clear communication between radiologists and clinicians. By providing a uniform lexicon and structured assessment categories (0–6), it ensures that a specific finding carries the same clinical weight regardless of the reporting radiologist. **Analysis of Options:** * **Option A (Correct):** BI-RADS provides a universal language for describing findings (e.g., mass margins, calcification morphology) and assigns a final assessment category that dictates management. * **Option B (Incorrect):** Prognosis is determined by TNM staging, histological grade, and molecular markers (ER/PR/HER2 status), not by the initial BI-RADS score. * **Option C (Incorrect):** BI-RADS is specific to breast imaging (Mammography, USG, MRI) and has no relevance to vascular conditions like brachial artery thrombosis. * **Option D (Incorrect):** While BI-RADS guides management, its primary goal is the standardization of the *imaging report* itself, rather than establishing clinical-pathological correlations. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete; needs further imaging (e.g., spot compression or comparison with old films). * **BI-RADS 3:** Probably benign (<2% risk of malignancy); management is **short-interval follow-up** (usually 6 months). * **BI-RADS 4 & 5:** Suspicious and Highly Suggestive; both require **tissue diagnosis (biopsy)**. * **BI-RADS 6:** Known biopsy-proven malignancy; used for monitoring response to neoadjuvant chemotherapy.

Q: A patient presents with a suspicious breast lump. Ultrasonography reports the lesion as BI-RADS-4. What is your inference?

Suspicious lesion requiring biopsy. **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized classification system used to communicate the risk of malignancy in breast imaging. **1. Why Option C is Correct:** **BI-RADS 4** is categorized as **"Suspicious."** Lesions in this category do not have the classic appearance of malignancy but possess features that make cancer a distinct possibility (risk of malignancy ranges from **>2% to <95%**). Therefore, the definitive management for any BI-RADS 4 lesion is a **tissue diagnosis (biopsy)**, typically via Ultrasound-guided Core Needle Biopsy. **2. Why Other Options are Incorrect:** * **Option A (BI-RADS 1 or 2):** BI-RADS 1 is a normal study; BI-RADS 2 represents definitely benign findings (e.g., simple cyst, stable fibroadenoma). Neither requires immediate intervention. * **Option B (BI-RADS 3):** These are "Probably Benign" lesions with a 95% risk). While they also require biopsy, the term "Suspicious" specifically defines Category 4. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete assessment; needs further imaging (e.g., comparison with old films or additional views). * **BI-RADS 4 Subdivisions:** 4A (Low suspicion, 2-10%), 4B (Moderate suspicion, 10-50%), and 4C (High suspicion, 50-95%). * **BI-RADS 6:** Confirmed malignancy (biopsy-proven) prior to definitive treatment like surgery or chemotherapy. * **Gold Standard:** For suspicious calcifications seen on mammography, **Stereotactic Biopsy** is the preferred method.

Q: Which of the following is NOT an indication for MRI in breast carcinoma?

Microcalcifications. **Explanation:** **1. Why Microcalcifications is the Correct Answer:** MRI has a very low sensitivity for detecting **microcalcifications**, which are a hallmark of early breast cancer, particularly Ductal Carcinoma In Situ (DCIS). Mammography remains the "Gold Standard" for evaluating microcalcifications. MRI relies on neoangiogenesis (contrast enhancement) rather than calcium deposits; therefore, it cannot reliably differentiate between benign and malignant calcifications. **2. Analysis of Incorrect Options:** * **High-risk cases (B):** MRI is the screening modality of choice for women with a >20-25% lifetime risk (e.g., BRCA1/2 mutations, Li-Fraumeni syndrome, or history of chest radiation). It has a higher sensitivity than mammography in dense breast tissue. * **Breast implant patients (C):** MRI is the most accurate method for evaluating implant integrity (detecting intra- and extracapsular ruptures) and for screening the surrounding breast parenchyma, which may be obscured on mammography. * **Lobular carcinoma in situ/Invasive Lobular Carcinoma (D):** Lobular neoplasia is often multifocal and multicentric. MRI is superior in determining the true extent of disease, detecting contralateral lesions, and identifying occult foci that mammography and ultrasound might miss. **Clinical Pearls for NEET-PG:** * **Best initial investigation for breast lump:** Triple Assessment (Clinical exam + Imaging + Biopsy). * **Best screening for general population:** Mammography. * **Best screening for young/high-risk/dense breasts:** MRI. * **MRI Contrast:** Gadolinium is used; malignant lesions show **rapid wash-in and rapid wash-out** (Type III curve). * **Indications for MRI:** Assessment of response to Neoadjuvant Chemotherapy (NACT), occult primary (axillary node positive, breast negative), and Paget’s disease of the nipple.

Q: What is a mammographic abnormality seen in breast cancer?

All of the above. **Explanation:** Mammography is the gold standard for breast cancer screening, and recognizing the classic signs of malignancy is crucial for NEET-PG. The correct answer is **All of the above** because breast cancer can manifest through several distinct radiological patterns: * **Clusters of Microcalcification (Option B):** This is often the earliest sign of ductal carcinoma in situ (DCIS). Malignant calcifications are typically pleomorphic (varying shapes), fine-linear, or branching (casting type), and are usually found in clusters (defined as >5 calcifications in 1 cm³). * **Change in Density (Option A):** Malignant lesions often appear as a **spiculated mass** or an irregular opacity. These masses are typically hyperdense compared to the surrounding glandular tissue and have "fuzzy" or ill-defined borders due to local infiltration. * **Change in Architecture (Option C):** Known as **Architectural Distortion**, this occurs when the normal radial arrangement of the breast parenchyma is disrupted without a visible central mass. It appears as lines radiating from a point or focal retraction of the edge of the parenchyma, often indicating invasive lobular carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS (Breast Imaging-Reporting and Data System):** A standardized scoring system (0–6) used to communicate the risk of malignancy. * **Most common mammographic sign of malignancy:** A spiculated, irregular mass. * **Most common sign of DCIS:** Microcalcifications. * **Skin Changes:** Look for skin thickening or "tethering" and nipple retraction, which are secondary signs of underlying malignancy. * **Screening:** Annual mammography is generally recommended starting at age 40 (standard guidelines).

Q: An MLO view of the left breast is shown. What is the MOST likely diagnosis?

Fibroadenomas. ***Fibroadenomas*** - Appear as **well-circumscribed**, **oval** or **lobulated masses** with smooth margins on mammography, often containing **coarse calcifications**. - Typically present as **mobile**, **painless lumps** in young women and may show **involuting calcifications** in older patients. *Papillomatosis* - Mammographically presents with **microcalcifications** in a **ductal distribution** rather than well-defined masses. - Associated with **nipple discharge** and appears as **branching microcalcifications** following ductal anatomy. *Fat necrosis* - Shows characteristic **rim calcifications** or **eggshell calcifications** around **lucent centers** representing necrotic fat. - Often has a history of **trauma** or **surgery** and appears as **irregular masses** with **spiculated margins** initially. *Oil cysts* - Appear as **round**, **lucent lesions** with **thin walls** and **rim calcifications** on mammography. - Represent **chronic fat necrosis** and show **fluid-fluid levels** or **fat-fluid levels** on imaging.

Q: What is the best investigation to differentiate scar tissue from recurrence after mastectomy for breast carcinoma?

PET scan. **Explanation:** The primary challenge in post-mastectomy imaging is distinguishing between **fibrosis (scar tissue)** and **tumor recurrence**, as both can appear as irregular, firm masses on anatomical imaging. **Why PET Scan is the Correct Answer:** PET scan (specifically FDG-PET) is a **functional/metabolic imaging** modality. It relies on the principle that malignant cells have a higher rate of glycolysis (Warburg effect) and thus take up more Fluorodeoxyglucose (FDG) than benign scar tissue. While scar tissue is metabolically inactive, recurrent tumor cells show high FDG uptake. This high **negative predictive value** makes PET the gold standard for differentiating post-surgical changes from active malignancy. **Why Other Options are Incorrect:** * **MRI (Option A):** While MRI has high sensitivity and is excellent for breast screening, it can sometimes show enhancement in fresh scar tissue (granulation tissue), leading to false positives. However, it is often the second-best choice if PET is unavailable. * **CT Scan (Option B):** CT lacks the soft-tissue resolution required to distinguish dense fibrous scars from small tumor nodules and is generally not used for primary breast evaluation. * **Mammography (Option D):** In a post-mastectomy patient, there is no breast tissue left to compress. While it can be used on the contralateral breast, it is ineffective for evaluating the chest wall scar for recurrence. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS:** Remember the Breast Imaging-Reporting and Data System; Category 6 is biopsy-proven malignancy. * **Best Initial Investigation (Symptomatic):** Ultrasound is often the first step for a palpable lump in the mastectomy scar. * **Best for Screening (High Risk):** Contrast-enhanced MRI. * **Microcalcifications:** Mammography is the most sensitive modality for detecting microcalcifications (an early sign of DCIS).

Q: Which of the following statements about MRI is NOT true?

MRI is not helpful in assessing breast implants.. **Explanation:** **1. Why Option A is the correct answer (The False Statement):** MRI is actually the **gold standard** for evaluating breast implants. It is highly sensitive for detecting both **intracapsular ruptures** (characterized by the "Linguine sign") and **extracapsular ruptures**. It is also superior to mammography and ultrasound in distinguishing between silicone granulomas and recurrent breast cancer. Therefore, stating that MRI is "not helpful" is factually incorrect. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** MRI has poor sensitivity for **microcalcifications**, which are often the earliest sign of ductal carcinoma in situ (DCIS). Mammography remains the modality of choice for detecting calcified lesions. * **Option C:** Unlike mammography or CT, MRI uses magnetic fields and radiofrequency pulses, involving **zero ionizing radiation**, making it safe for frequent screening in high-risk young patients. * **Option D:** Strong magnetic fields can malfunction or displace older **cardiac pacemakers** and other ferromagnetic implants (e.g., cochlear implants, certain aneurysm clips), making them a classic contraindication. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Needs further imaging. * **Linguine Sign:** Pathognomonic for intracapsular breast implant rupture on MRI. * **Indications for Breast MRI:** Screening high-risk patients (BRCA mutations), assessing occult primary breast cancer, and evaluating neoadjuvant chemotherapy response. * **Contrast:** Gadolinium is used; malignant lesions typically show **rapid uptake and rapid washout** (Type III curve).

Breast Imaging Indian Medical PG Practice Questions and MCQs

Question 1: For normal mammography, what is the nominal focal size of the X-ray tube used?

A. 0.2-0.25 mm
B. 0.3-0.35 mm (Correct Answer)
C. 0.4-0.45 mm
D. 0.45-0.50 mm

Explanation: In mammography, high spatial resolution is critical for detecting tiny structures like microcalcifications. The focal spot size directly influences **geometric blurring** (penumbra); a smaller focal spot results in a sharper image. ### 1. Why Option B is Correct For **routine (normal) mammography**, a nominal focal spot size of **0.3 mm** (typically ranging from 0.3 to 0.35 mm) is the standard. This size provides an optimal balance: it is small enough to ensure high detail for screening while being large enough to withstand the heat generated by the X-ray tube during standard exposures without damaging the anode. ### 2. Why Other Options are Incorrect * **Option A (0.2-0.25 mm):** This is too large for magnification but smaller than the standard for routine screening. * **Options C & D (0.4-0.5 mm):** These sizes are used in general radiography (e.g., Chest X-rays, where focal spots are often 0.6–1.2 mm). In mammography, such large spots would cause excessive geometric blurring, making it impossible to see fine architectural distortions. ### 3. High-Yield Clinical Pearls for NEET-PG * **Magnification Mammography:** When a specific area needs to be magnified, a much smaller focal spot of **0.1 mm** (range 0.1–0.15 mm) is used to compensate for the increased blurring caused by the air gap. * **Anode Material:** Usually **Molybdenum (Mo)** or Rhodium (Rh) is used to produce low-energy (soft) X-rays (25–30 kVp) for better soft-tissue contrast. * **Orientation:** The cathode is placed over the **base of the breast** (chest wall) and the anode over the **apex** (nipple) to utilize the "Heel Effect" for uniform density.

Question 2: What is the typical radiation dose delivered during mammography?

A. 0.1 Gray/study
B. 0.01 centiGray/study
C. 0.1 centiGray/study (Correct Answer)
D. 0.01 Gray/study

Explanation: ### Explanation **1. Why Option C is Correct:** The radiation dose in mammography is measured as the **Mean Glandular Dose (MGD)**, which represents the average dose to the radiosensitive glandular tissue of the breast. For a standard two-view screening mammogram (per breast), the typical dose is approximately **1 to 2 mGy (0.1 to 0.2 rad)**. Since **1 rad = 1 centiGray (cGy)**, a dose of 0.1 rad is equivalent to **0.1 cGy**. This level of radiation is considered very low and is roughly equivalent to the amount of natural background radiation a person receives over seven weeks. **2. Why Other Options are Incorrect:** * **Option A (0.1 Gray):** This is equivalent to 100 mGy. This dose is far too high for diagnostic imaging and would be closer to levels used in therapeutic radiation or causing deterministic effects. * **Option B (0.01 cGy):** This is 0.1 mGy, which is too low to produce a diagnostic quality image of dense breast tissue. * **Option D (0.01 Gray):** This is equivalent to 10 mGy (1 rad). While some complex interventional procedures might reach this level, it is significantly higher than the standard dose for a screening mammogram. **3. High-Yield Clinical Pearls for NEET-PG:** * **Target/Filter Material:** Mammography uses low-energy X-rays (typically **25–35 kVp**) to maximize soft tissue contrast. Common target/filter combinations are **Molybdenum/Molybdenum** or **Rhodium**. * **MQSA Requirement:** The Mammography Quality Standards Act (MQSA) mandates that the dose should not exceed **3 mGy (0.3 cGy)** per view with a grid. * **Screening Guidelines:** In India, the general recommendation is annual or biennial screening starting at age 40–50 years. * **Risk vs. Benefit:** The risk of radiation-induced breast cancer is negligible compared to the benefit of early detection of spontaneous breast cancer.

Question 3: Which of the following is NOT an indication of malignancy on mammography?

A. Nodular calcification (Correct Answer)
B. Speckled margin
C. Attenuated architecture
D. Irregular mass

Explanation: ### Explanation In mammography, the primary goal is to differentiate between benign and malignant features based on mass morphology, margins, and calcification patterns. **1. Why "Nodular Calcification" is the correct answer:** Nodular (or "popcorn-like") calcifications are typically large, coarse, and well-defined. These are classic features of **benign** lesions, most commonly seen in **involuting fibroadenomas**. Malignant calcifications, by contrast, are usually pleomorphic, fine-linear, or branching (casting type), representing necrotic debris within ducts (as seen in DCIS). **2. Analysis of Incorrect Options (Malignant Features):** * **Speckled (Spiculated) Margin:** This is the most specific mammographic sign of malignancy. It represents the infiltration of cancer cells into surrounding tissue and the subsequent desmoplastic reaction. * **Attenuated (Distorted) Architecture:** Architectural distortion refers to the pulling or tethering of normal breast parenchyma without a visible central mass. While it can occur in post-surgical scars, in a screening context, it is highly suspicious for invasive lobular or ductal carcinoma. * **Irregular Mass:** Malignant tumors grow haphazardly, leading to an irregular shape. Benign lesions are more likely to be round, oval, or circumscribed. **3. High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS Classification:** Used for standardized reporting. BI-RADS 4 and 5 indicate high suspicion of malignancy. * **Most specific sign of malignancy:** Spiculated margins. * **Benign Calcifications:** Popcorn (Fibroadenoma), Eggshell/Rim (Oil cysts), and Teardrop (Milk of calcium). * **Malignant Calcifications:** Fine pleomorphic or fine-linear branching (BI-RADS 5). * **Initial Investigation:** Mammography is the gold standard for screening women >40 years; Ultrasound is preferred for women <30 years or during pregnancy/lactation.

Question 4: What is the primary purpose of the BIRADS score?

A. To maintain uniformity in the reporting of imaging findings of various breast diseases (Correct Answer)
B. To prognosticate breast cancer
C. To evaluate the effect of brachial artery thrombosis
D. To establish a clinicoradiological association of breast malignancy

Explanation: **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized quality assurance tool developed by the American College of Radiology (ACR). Its primary objective is to **standardize breast imaging reporting**, reduce ambiguity in interpretations, and facilitate clear communication between radiologists and clinicians. By providing a uniform lexicon and structured assessment categories (0–6), it ensures that a specific finding carries the same clinical weight regardless of the reporting radiologist. **Analysis of Options:** * **Option A (Correct):** BI-RADS provides a universal language for describing findings (e.g., mass margins, calcification morphology) and assigns a final assessment category that dictates management. * **Option B (Incorrect):** Prognosis is determined by TNM staging, histological grade, and molecular markers (ER/PR/HER2 status), not by the initial BI-RADS score. * **Option C (Incorrect):** BI-RADS is specific to breast imaging (Mammography, USG, MRI) and has no relevance to vascular conditions like brachial artery thrombosis. * **Option D (Incorrect):** While BI-RADS guides management, its primary goal is the standardization of the *imaging report* itself, rather than establishing clinical-pathological correlations. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete; needs further imaging (e.g., spot compression or comparison with old films). * **BI-RADS 3:** Probably benign (<2% risk of malignancy); management is **short-interval follow-up** (usually 6 months). * **BI-RADS 4 & 5:** Suspicious and Highly Suggestive; both require **tissue diagnosis (biopsy)**. * **BI-RADS 6:** Known biopsy-proven malignancy; used for monitoring response to neoadjuvant chemotherapy.

Question 5: A patient presents with a suspicious breast lump. Ultrasonography reports the lesion as BI-RADS-4. What is your inference?

A. Benign lesion requiring no follow-up
B. Probably benign lesion requiring follow-up
C. Suspicious lesion requiring biopsy (Correct Answer)
D. Highly suggestive of malignancy

Explanation: **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized classification system used to communicate the risk of malignancy in breast imaging. **1. Why Option C is Correct:** **BI-RADS 4** is categorized as **"Suspicious."** Lesions in this category do not have the classic appearance of malignancy but possess features that make cancer a distinct possibility (risk of malignancy ranges from **>2% to <95%**). Therefore, the definitive management for any BI-RADS 4 lesion is a **tissue diagnosis (biopsy)**, typically via Ultrasound-guided Core Needle Biopsy. **2. Why Other Options are Incorrect:** * **Option A (BI-RADS 1 or 2):** BI-RADS 1 is a normal study; BI-RADS 2 represents definitely benign findings (e.g., simple cyst, stable fibroadenoma). Neither requires immediate intervention. * **Option B (BI-RADS 3):** These are "Probably Benign" lesions with a <2% risk of malignancy. The standard management is **short-interval follow-up** (usually at 6 months) rather than immediate biopsy. * **Option D (BI-RADS 5):** These lesions are "Highly Suggestive of Malignancy" (>95% risk). While they also require biopsy, the term "Suspicious" specifically defines Category 4. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete assessment; needs further imaging (e.g., comparison with old films or additional views). * **BI-RADS 4 Subdivisions:** 4A (Low suspicion, 2-10%), 4B (Moderate suspicion, 10-50%), and 4C (High suspicion, 50-95%). * **BI-RADS 6:** Confirmed malignancy (biopsy-proven) prior to definitive treatment like surgery or chemotherapy. * **Gold Standard:** For suspicious calcifications seen on mammography, **Stereotactic Biopsy** is the preferred method.

Question 6: Which of the following is NOT an indication for MRI in breast carcinoma?

A. Microcalcifications (Correct Answer)
B. High-risk cases
C. Breast implant patients
D. Lobular carcinoma in situ

Explanation: **Explanation:** **1. Why Microcalcifications is the Correct Answer:** MRI has a very low sensitivity for detecting **microcalcifications**, which are a hallmark of early breast cancer, particularly Ductal Carcinoma In Situ (DCIS). Mammography remains the "Gold Standard" for evaluating microcalcifications. MRI relies on neoangiogenesis (contrast enhancement) rather than calcium deposits; therefore, it cannot reliably differentiate between benign and malignant calcifications. **2. Analysis of Incorrect Options:** * **High-risk cases (B):** MRI is the screening modality of choice for women with a >20-25% lifetime risk (e.g., BRCA1/2 mutations, Li-Fraumeni syndrome, or history of chest radiation). It has a higher sensitivity than mammography in dense breast tissue. * **Breast implant patients (C):** MRI is the most accurate method for evaluating implant integrity (detecting intra- and extracapsular ruptures) and for screening the surrounding breast parenchyma, which may be obscured on mammography. * **Lobular carcinoma in situ/Invasive Lobular Carcinoma (D):** Lobular neoplasia is often multifocal and multicentric. MRI is superior in determining the true extent of disease, detecting contralateral lesions, and identifying occult foci that mammography and ultrasound might miss. **Clinical Pearls for NEET-PG:** * **Best initial investigation for breast lump:** Triple Assessment (Clinical exam + Imaging + Biopsy). * **Best screening for general population:** Mammography. * **Best screening for young/high-risk/dense breasts:** MRI. * **MRI Contrast:** Gadolinium is used; malignant lesions show **rapid wash-in and rapid wash-out** (Type III curve). * **Indications for MRI:** Assessment of response to Neoadjuvant Chemotherapy (NACT), occult primary (axillary node positive, breast negative), and Paget’s disease of the nipple.

Question 7: What is a mammographic abnormality seen in breast cancer?

A. Change in density
B. Clusters of microcalcification
C. Change in architecture
D. All of the above (Correct Answer)

Explanation: **Explanation:** Mammography is the gold standard for breast cancer screening, and recognizing the classic signs of malignancy is crucial for NEET-PG. The correct answer is **All of the above** because breast cancer can manifest through several distinct radiological patterns: * **Clusters of Microcalcification (Option B):** This is often the earliest sign of ductal carcinoma in situ (DCIS). Malignant calcifications are typically pleomorphic (varying shapes), fine-linear, or branching (casting type), and are usually found in clusters (defined as >5 calcifications in 1 cm³). * **Change in Density (Option A):** Malignant lesions often appear as a **spiculated mass** or an irregular opacity. These masses are typically hyperdense compared to the surrounding glandular tissue and have "fuzzy" or ill-defined borders due to local infiltration. * **Change in Architecture (Option C):** Known as **Architectural Distortion**, this occurs when the normal radial arrangement of the breast parenchyma is disrupted without a visible central mass. It appears as lines radiating from a point or focal retraction of the edge of the parenchyma, often indicating invasive lobular carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS (Breast Imaging-Reporting and Data System):** A standardized scoring system (0–6) used to communicate the risk of malignancy. * **Most common mammographic sign of malignancy:** A spiculated, irregular mass. * **Most common sign of DCIS:** Microcalcifications. * **Skin Changes:** Look for skin thickening or "tethering" and nipple retraction, which are secondary signs of underlying malignancy. * **Screening:** Annual mammography is generally recommended starting at age 40 (standard guidelines).

Question 8: An MLO view of the left breast is shown. What is the MOST likely diagnosis?

A. Papillomatosis
B. Fat necrosis
C. Oil cysts
D. Fibroadenomas (Correct Answer)

Explanation: ***Fibroadenomas*** - Appear as **well-circumscribed**, **oval** or **lobulated masses** with smooth margins on mammography, often containing **coarse calcifications**. - Typically present as **mobile**, **painless lumps** in young women and may show **involuting calcifications** in older patients. *Papillomatosis* - Mammographically presents with **microcalcifications** in a **ductal distribution** rather than well-defined masses. - Associated with **nipple discharge** and appears as **branching microcalcifications** following ductal anatomy. *Fat necrosis* - Shows characteristic **rim calcifications** or **eggshell calcifications** around **lucent centers** representing necrotic fat. - Often has a history of **trauma** or **surgery** and appears as **irregular masses** with **spiculated margins** initially. *Oil cysts* - Appear as **round**, **lucent lesions** with **thin walls** and **rim calcifications** on mammography. - Represent **chronic fat necrosis** and show **fluid-fluid levels** or **fat-fluid levels** on imaging.

Question 9: What is the best investigation to differentiate scar tissue from recurrence after mastectomy for breast carcinoma?

A. MRI
B. CT scan
C. PET scan (Correct Answer)
D. Mammography

Explanation: **Explanation:** The primary challenge in post-mastectomy imaging is distinguishing between **fibrosis (scar tissue)** and **tumor recurrence**, as both can appear as irregular, firm masses on anatomical imaging. **Why PET Scan is the Correct Answer:** PET scan (specifically FDG-PET) is a **functional/metabolic imaging** modality. It relies on the principle that malignant cells have a higher rate of glycolysis (Warburg effect) and thus take up more Fluorodeoxyglucose (FDG) than benign scar tissue. While scar tissue is metabolically inactive, recurrent tumor cells show high FDG uptake. This high **negative predictive value** makes PET the gold standard for differentiating post-surgical changes from active malignancy. **Why Other Options are Incorrect:** * **MRI (Option A):** While MRI has high sensitivity and is excellent for breast screening, it can sometimes show enhancement in fresh scar tissue (granulation tissue), leading to false positives. However, it is often the second-best choice if PET is unavailable. * **CT Scan (Option B):** CT lacks the soft-tissue resolution required to distinguish dense fibrous scars from small tumor nodules and is generally not used for primary breast evaluation. * **Mammography (Option D):** In a post-mastectomy patient, there is no breast tissue left to compress. While it can be used on the contralateral breast, it is ineffective for evaluating the chest wall scar for recurrence. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS:** Remember the Breast Imaging-Reporting and Data System; Category 6 is biopsy-proven malignancy. * **Best Initial Investigation (Symptomatic):** Ultrasound is often the first step for a palpable lump in the mastectomy scar. * **Best for Screening (High Risk):** Contrast-enhanced MRI. * **Microcalcifications:** Mammography is the most sensitive modality for detecting microcalcifications (an early sign of DCIS).

Question 10: Which of the following statements about MRI is NOT true?

A. MRI is not helpful in assessing breast implants. (Correct Answer)
B. MRI is not good for detecting calcified lesions.
C. MRI involves no radiation exposure.
D. MRI is contraindicated in patients with cardiac pacemakers.

Explanation: **Explanation:** **1. Why Option A is the correct answer (The False Statement):** MRI is actually the **gold standard** for evaluating breast implants. It is highly sensitive for detecting both **intracapsular ruptures** (characterized by the "Linguine sign") and **extracapsular ruptures**. It is also superior to mammography and ultrasound in distinguishing between silicone granulomas and recurrent breast cancer. Therefore, stating that MRI is "not helpful" is factually incorrect. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** MRI has poor sensitivity for **microcalcifications**, which are often the earliest sign of ductal carcinoma in situ (DCIS). Mammography remains the modality of choice for detecting calcified lesions. * **Option C:** Unlike mammography or CT, MRI uses magnetic fields and radiofrequency pulses, involving **zero ionizing radiation**, making it safe for frequent screening in high-risk young patients. * **Option D:** Strong magnetic fields can malfunction or displace older **cardiac pacemakers** and other ferromagnetic implants (e.g., cochlear implants, certain aneurysm clips), making them a classic contraindication. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Needs further imaging. * **Linguine Sign:** Pathognomonic for intracapsular breast implant rupture on MRI. * **Indications for Breast MRI:** Screening high-risk patients (BRCA mutations), assessing occult primary breast cancer, and evaluating neoadjuvant chemotherapy response. * **Contrast:** Gadolinium is used; malignant lesions typically show **rapid uptake and rapid washout** (Type III curve).

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Male Breast Imaging

Practice Questions

Mammography Techniques

Practice Questions

BI-RADS Classification

Practice Questions

Breast Ultrasonography

Practice Questions

Breast MRI

Practice Questions

Digital Breast Tomosynthesis

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Detection and Diagnosis

Practice Questions

Interventional Breast Procedures

Practice Questions

Breast Cancer Screening

Practice Questions

Male Breast Imaging

Practice Questions

Post-treatment Breast Imaging

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free